Results 231 to 240 of about 99,125 (300)

Productivity losses and treatment cost of benign prostatic hyperplasia in Ghana. [PDF]

PLoS One
Dadee-Seshie DS, Agbeteti SG, Kpankyaano B, Adamu AF, Adanu SK, Alhassan Y, Dalaba MA, Adanu KK.   +7 more
europepmc   +1 more source

Fasting blood glucose to HDL-C ratio as a potential biomarker for prostate cancer risk classification. [PDF]

BMC Urol
Özkan S, Börekoğlu A.
europepmc   +1 more source

HUBUNGAN ANTARA DERAJAT INTRAVESICAL PROSTATIC PROTRUSSION DENGAN Q MAX, VOLUME PROSTAT, DAN INTERNATIONAL PROSTATE SYMPTOM SCORE PADA PASIEN BPH DENGAN LUTS TANPA KOMPLIKASI

, 1970
Musa As'ari, Sabilal Alif, Adi Santoso, J P Widodo   +3 more
openalex   +1 more source

Postmortem Serum Prostate-Specific Antigen as a Potential Marker for Prostatic Disease: A Forensic Exploratory Study. [PDF]

Cureus
Matsumoto S, Takasu S.
europepmc   +1 more source

Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review

, 2012
Roderick MacDonald, James Tacklind, Indulis Rutks, Timothy J Wilt   +3 more
openalex   +2 more sources

Unveiling the causal relationships between gut microbiota, circulating metabolic biomarkers, and benign prostate hyperplasia: A Mendelian randomization study. [PDF]

Medicine (Baltimore)
Yan Y, Hu M, Liu C, Liu Q, Xiong T, Su K.   +5 more
europepmc   +1 more source

Abstract 123A: The critical role of interleukin-8 chemokine axis in the development of benign prostatic hyperplasia (BPH)

, 2019
Diandra K. Smith, Natasha Venugopal, Martha K. Terris, Bal L. Lokeshwar   +3 more
openalex   +1 more source

Developing an interpretable clinical-radiomics machine learning model using whole transition zone MRI analysis for improving diagnosis of transition zone prostate cancer. [PDF]

Front Oncol
Yang J, Jiang N, Zhang Y, Yang L, Xia L, Ren Y, Xu H, Li Z, Wang J, Cui F.   +9 more
europepmc   +1 more source

Metabolic syndrome and BPH: What do we know?

, 2017
Amit Agrawal
openalex   +2 more sources